Evaluating PD-1/PD-L1 in rectal cancer by quantitative fluorescence molecular endoscopy.

2023-507106-13-00 Protocol 17651 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 12 Jan 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol 17651

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 23
Countries 1
Sites 1

Locally advanced rectal cancer

Key facts

Sponsor
Universitair Medisch Centrum Groningen
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04], Diseases [C] - Digestive System Diseases [C06]
Trial duration
12 Jan 2026 → ongoing
Decision date (initial)
2024-03-18
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-507106-13-00
ClinicalTrials.gov
NCT06304597

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Locally advanced rectal cancer

VersionLevelCodeTermSystem organ class
20.0 PT 10038038 Rectal cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Universitair Medisch Centrum Groningen

Sponsor organisation
Universitair Medisch Centrum Groningen
Address
Hanzeplein 1
City
Groningen
Postcode
9713 GZ
Country
Netherlands

Scientific contact point

Organisation
Universitair Medisch Centrum Groningen
Contact name
W.B. Nagengast

Public contact point

Organisation
Universitair Medisch Centrum Groningen
Contact name
W.B. Nagengast

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 23 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Universitair Medisch Centrum Groningen
Gastroenterology and Hepatology, Hanzeplein 1, 9713 GZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2026-01-12 2026-01-12

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-11-21 Netherlands Acceptable
2024-03-18
2024-03-18
2 SUBSTANTIAL MODIFICATION SM-1 2024-09-13 Netherlands Acceptable
2024-12-06
2024-12-06
3 SUBSTANTIAL MODIFICATION SM-2 2025-09-04 Netherlands Acceptable
2025-12-01
2025-12-08